SITC has provided comment on the recently posted "Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies; Guidance for Industry - Draft Guidance". SITC was pleased to see FDA incorporate feedback and topics that have stemmed from recent SITC DEI efforts including a corporate roundtable in 2022. Please find SITC's full comment letter HERE.
#FDA#Policy